G1 Therapeutics Inc Quick Ratio (GTHX) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
G1 Therapeutics Inc   (NASDAQ: GTHX)

G1 Therapeutics Inc 's Quick Ratio

GTHX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 1.62 a new company low.

Within Major Pharmaceutical Preparations industry 316 other companies have achieved higher Quick Ratio than G1 Therapeutics Inc in second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 120 to 1344.

Explain Quick Ratio?
How much Cash & cash equivalents GTHX´s has?
What are GTHX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GTHX Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change 10.59 % -3.23 % -16.5 % -9.37 % -8.97 %
Y / Y Cash & cash equivalent Change -41.74 % -43.96 % -43.37 % -23.28 % -27.6 %
Quick Ratio MRQ 1.62 2 2.76 2.8 3.07
GTHX's Total Ranking # 1344 # 120 # 295 # 269 # 986
Seq. Current Liabilities Change 15.03 % 9.72 % -11.7 % -0.76 % 0.66 %
Seq. Cash & cash equivalent Change -6.84 % -20.66 % -12.93 % -9.48 % -10.39 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 317
Healthcare Sector # 570
Overall Market # 1344


Quick Ratio Statistics
High Average Low
30.11 10.51 1.62
(Mar 31 2019)   (Jun 30 2024)




Financial Statements
G1 Therapeutics Inc 's Current Liabilities $ 38 Millions Visit GTHX's Balance sheet
G1 Therapeutics Inc 's Cash & cash equivalent $ 61 Millions Visit GTHX's Balance sheet
Source of GTHX's Sales Visit GTHX's Sales by Geography


Cumulative G1 Therapeutics Inc 's Quick Ratio

GTHX's Quick Ratio for the trailling 12 Months

GTHX Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -4.88 % -9.59 % -9.65 % -0.1 % 10.76 %
Y / Y Cash & cash equivalent TTM Growth -38.1 % -34.52 % -33.27 % -31.46 % -35.73 %
Quick Ratio TTM 2.27 2.66 3.03 3.36 3.48
Total Ranking TTM # 3924 # 3383 # 3361 # 3335 # 3326
Seq. Current Liabilities TTM Growth 2.77 % -0.83 % -4.29 % -2.48 % -2.32 %
Seq. Cash & cash equivalent TTM Growth -12.58 % -12.88 % -13.68 % -5.86 % -7.52 %

Quick ratio ranking by company, industry and sector >> Back to GTHX Financial Strength Comparisons >> Go to Compare GTHX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2024 to $37.50 millions, cumulative Quick Ratio decreased to 2.27 below the G1 Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 485 other companies have achieved higher Quick Ratio than G1 Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 3383 to 3924.

Explain Quick Ratio?
How much Cash & cash equivalents GTHX´s has?
What are GTHX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 486
Healthcare Sector # 1010
Within the Market # 3924


trailing twelve months Quick Ratio Statistics
High Average Low
25.82 10.58 2.27
(Jun 30 2019)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Rein Therapeutics Inc   4.44 $ 21.917  Millions$ 4.937  Millions
Amylyx Pharmaceuticals Inc   4.42 $ 309.812  Millions$ 70.081  Millions
Pacira Biosciences inc   4.36 $ 404.226  Millions$ 92.690  Millions
Citius Pharmaceuticals Inc   4.32 $ 17.949  Millions$ 4.152  Millions
Immuron Limited  4.32 $ 7.784  Millions$ 1.802  Millions
Talphera Inc   4.28 $ 14.023  Millions$ 3.274  Millions
Rafael Holdings Inc  4.25 $ 67.440  Millions$ 15.868  Millions
Puretech Health Plc  4.24 $ 308.478  Millions$ 72.833  Millions
Theravance Biopharma inc   4.19 $ 96.078  Millions$ 22.946  Millions
Inovio Pharmaceuticals Inc   4.18 $ 110.422  Millions$ 26.400  Millions
Addex Therapeutics Ltd  4.17 $ 3.685  Millions$ 0.885  Millions
Bolt Biotherapeutics Inc   4.12 $ 73.697  Millions$ 17.900  Millions
Cormedix Inc   4.10 $ 45.610  Millions$ 11.111  Millions
Alx Oncology Holdings Inc  4.08 $ 156.723  Millions$ 38.449  Millions
Catalyst Pharmaceuticals Inc   4.07 $ 375.693  Millions$ 92.318  Millions
Arrowhead Pharmaceuticals Inc   4.05 $ 367.272  Millions$ 90.661  Millions
Shattuck Labs Inc   4.04 $ 60.693  Millions$ 15.026  Millions
Inmed Pharmaceuticals Inc  4.01 $ 8.583  Millions$ 2.142  Millions
Indaptus Therapeutics Inc   4.00 $ 7.302  Millions$ 1.825  Millions
Marker Therapeutics inc   3.96 $ 7.800  Millions$ 1.972  Millions
Enanta Pharmaceuticals Inc  3.95 $ 230.085  Millions$ 58.231  Millions
Filana Therapeutics Inc   3.91 $ 207.291  Millions$ 52.998  Millions
Lipella Pharmaceuticals Inc   3.89 $ 1.187  Millions$ 0.305  Millions
Day One Biopharmaceuticals Inc   3.87 $ 361.866  Millions$ 93.516  Millions
Longeveron Inc   3.86 $ 12.375  Millions$ 3.210  Millions
Unity Biotechnology Inc   3.85 $ 33.984  Millions$ 8.818  Millions
Proqr Therapeutics N v   3.84 $ 167.337  Millions$ 43.570  Millions
Processa Pharmaceuticals Inc   3.82 $ 5.571  Millions$ 1.459  Millions
Schrodinger Inc   3.78 $ 377.289  Millions$ 99.759  Millions
Aurinia Pharmaceuticals Inc   3.73 $ 331.905  Millions$ 88.995  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.